Detalhe da pesquisa
1.
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Blood
; 140(22): 2348-2357, 2022 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35921541
2.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36632738
3.
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.
Blood
; 134(10): 798-801, 2019 09 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31292118
4.
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies.
Am J Hematol
; 95(12): 1473-1478, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32780514
5.
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Am J Hematol
; 94(11): 1193-1199, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31378966
6.
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
Am J Hematol
; 99(5): 982-984, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38343033
7.
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Future Oncol
; 15(19): 2227-2239, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-31137964
8.
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.
Br J Haematol
; 201(2): 353-356, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36793194
9.
Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Future Oncol
; 14(8): 681-697, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29243946
10.
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
Haematologica
; 107(6): 1470-1473, 2022 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35199505
11.
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib.
Hematol Oncol
; 40(5): 1105-1108, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35656838
12.
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.
Hematol Oncol
; 40(5): 1100-1104, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35613703
13.
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Am J Hematol
; 97(5): E176-E180, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35170793
14.
Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience.
Hematol Oncol
; 38(1): 111-113, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31852014
15.
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia.
Hematol Oncol
; 37(4): 508-512, 2019 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-31335982
16.
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review.
Cancers (Basel)
; 16(8)2024 Apr 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38672557
17.
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.
EClinicalMedicine
; 72: 102592, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38633575
18.
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.
Cancers (Basel)
; 15(5)2023 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36900295
19.
SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?
Clin Lymphoma Myeloma Leuk
; 22(6): 356-361, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34969641
20.
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
Ther Adv Hematol
; 13: 20406207221127550, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36246422